XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 30 filers reported holding XENON PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $320 | -99.9% | 9,371 | -6.2% | 0.03% | -11.1% |
Q3 2022 | $361,000 | -15.7% | 9,990 | -28.6% | 0.04% | -28.0% |
Q1 2022 | $428,000 | +177.9% | 13,993 | +3.4% | 0.05% | +66.7% |
Q1 2020 | $154,000 | +275.6% | 13,539 | +4.1% | 0.03% | +275.0% |
Q2 2017 | $41,000 | – | 13,001 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |